Affiliation:
1. King Fahad Medical City
Abstract
Abstract
Background: Chemotherapy-induced febrile neutropenia (CIFN) is a major dose-limiting toxicity of chemotherapy. It is associated with an overall hospitalization rate of 35% and an average mortality of 9.5% (2.6% -21.4%).
Granulocyte colony-stimulating factors (GCSFs) are often prescribed as primary or secondary prophylaxis and to manage chemotherapy induced febrile neutropenia (CIFN). The American Society of Clinical Oncology (ASCO) guidelines exists to optimize the use of GCSFs.
The main aim was to quantify the inappropriate use of the GCSFs in Primary, secondary prophylaxis and in acute (CIFN) management using the ASCO guidelines as a reference.
Methods: This is a retrospective cohort study included 204 adult randomly chosen patients with solid tumors on chemotherapy.
Results: A total of 204 patients were included . Overall, GCSFs were prescribed appropriately in 104 (51%) patients and in 100 (49 %) was considered inappropriate.
The median duration of GCFs was 5 days in most of the patients.
Conclusions: The inappropriate use of GCSFs is common in terms of indications and duration in adult patients with solid tumor receiving chemotherapy. Adherence to guideline will optimize use.
Publisher
Research Square Platform LLC
Reference17 articles.
1. 1. Klastersky JA, Meert AP. Understanding the risk for infection in patients with neutropenia. Intensive Care Med. 2016;42(2):268 − 70.
2. 2. Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med. 2014;3(2):434 − 44.
3. 3. Karimi F, Ashrafi F, Moghaddas A, Derakhshandeh A. Management of Febrile Neutropenia: A Description of Clinical and Microbiological Findings by Focusing on Risk Factors and Pitfalls. J Res Pharm Pract. 2018;7(3):147 − 56.
4. 4. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-67.
5. 5. Ibayashi Y, Ohyama H, Hashimoto Y, Sakatani K, Morimoto S, Takahashi H, et al. [A case report of interstitial pneumonia caused by granulocyte colony-stimulating factor]. No Shinkei Geka. 1994;22(2):169 − 74.